Evidence map›Paper›PMID 38095672›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Detection of metabolic adaptation in a triple-negative breast cancer animal model with [

Andres A Kohan, Mathieu Lupien, David Cescon, Geneviève Deblois, Manuela Ventura, Ur Metser, Patrick Veit-Haibach

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Andres A KohanUniversity Medical Imaging Toronto, Toronto Joint Department Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, 263 McCaul St 4th floor, Toronto, ON, M5T 1W7, Canada. Andres.Kohan@uhn.ca.ORCID 0000-0003-3592-3000
Mathieu LupienPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
David CesconPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Geneviève DebloisInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada.
Manuela VenturaSTTARR Innovation Centre, University Health Network, Toronto, Ontario, Canada.
Ur MetserUniversity Medical Imaging Toronto, Toronto Joint Department Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, 263 McCaul St 4th floor, Toronto, ON, M5T 1W7, Canada.
Patrick Veit-HaibachUniversity Medical Imaging Toronto, Toronto Joint Department Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, 263 McCaul St 4th floor, Toronto, ON, M5T 1W7, Canada.
University Health Network · CAInstitute for Research in Immunology and Cancer · CAOntario Institute for Cancer Research · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTest the feasibility of an image-based method to identify taxane resistance in mouse bearing triple-negative breast cancer (TNBC) tumor xenografts.

methodsXenograft tumor-bearing mice from paclitaxel-sensitive and paclitaxel-resistant TNBC cells (MDA-MD-346) were generated by orthotopic injection into female NOD-SCID mice. When tumors reached 100-150 mm

resultsFrom fifteen mice scanned, five had taxane-sensitive cell line tumors of which two underwent taxol-based treatment. From the remaining 10 mice with taxane-resistant cell line tumors, four underwent taxol-based treatment. Only 13 mice had the tumor sample analyzed histologically. When normalized to the blood pool, both cell lines showed differences in metabolic uptake before and after treatment.

conclusionsTreated and untreated taxane-sensitive and taxane-resistant cell lines have different metabolic properties that could be leveraged before the start of chemotherapy.

Indexed as

Positron Emission Tomography Computed TomographyTriple Negative Breast NeoplasmsAnimalsCell Line, TumorDrug ResistanceFemaleHumansMiceMice, Inbred NODMice, SCIDModels, AnimalPaclitaxelPositron-Emission TomographyXenograft Model Antitumor AssaysPaclitaxelDrug resistanceNOD micePET/CTSCID miceTriple-negative breast neoplasm

Identifiers

PMID38095672
OpenAlexW4389738425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.